RxDoctor Payments Data

James Weingart, MD

Family Medicine · Thornton, CONPI 1679529440

Payments from drug & device makers

$9,314in general payments, 2019–2025

Across 533 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$967
  • Novo Nordisk$772
  • Boehringer Ingelheim$698
  • Lilly USA, LLC$668
  • Pfizer$542
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$9,18999%
  • Education$1141%
  • Gifts$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,314 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$7,398
Medicare patients
31
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$50,443
EliquisApixaban30$40,105
FarxigaDapagliflozin Propanediol22$31,252
JardianceEmpagliflozin22$27,134
OzempicSemaglutide13$24,729
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,357
Testosterone13$3,018
Omeprazole60$1,683
Atorvastatin Calcium200$1,515
Gabapentin72$1,506
Clonazepam41$1,471
Lisinopril151$1,185
Estradiol28$1,179
Levothyroxine Sodium89$801
RizatriptanRizatriptan Benzoate12$755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$668$50,44347 claims
PfizerEliquis$542$40,10530 claims
AstraZenecaFarxiga$967$31,25222 claims
Boehringer IngelheimJardiance$698$27,13422 claims
Novo NordiskOzempic$772$24,72913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Thornton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →